![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Springe zu: 2024
Anzahl der Publikationen: 1
2024
Dreyling, Martin; Doorduijn, Jeanette; Giné, Eva; Jerkeman, Mats; Walewski, Jan; Hutchings, Martin; Mey, Ulrich; Riise, Jon; Trneny, Marek; Vergote, Vibeke; Shpilberg, Ofer; Gomes da Silva, Maria; Leppä, Sirpa; Jiang, Linmiao; Stilgenbauer, Stephan; Kerkhoff, Andrea; Jachimowicz, Ron D; Celli, Melania; Hess, Georg; Arcaini, Luca; Visco, Carlo; Meerten, Tom van; Wirths, Stefan; Zinzani, Pier Luigi; Novak, Urban; Herhaus, Peter; Benedetti, Fabio; Sonnevi, Kristina; Hanoun, Christine; Hänel, Matthias; Dierlamm, Judith; Pott, Christiane; Klapper, Wolfram; Gözel, Döndü; Schmidt, Christian; Unterhalt, Michael; Ladetto, Marco und Hoster, Eva 
ORCID: https://orcid.org/0000-0002-0749-1389
(2024):
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
In: Lancet, Bd. 403, Nr. 10441: S. 2293-2306
ORCID: https://orcid.org/0000-0002-0749-1389
(2024):
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
In: Lancet, Bd. 403, Nr. 10441: S. 2293-2306